Cough monitoring system facilitates clinical trials and enables development of treatments for patients with refractory chronic cough

  • Smith, Jacky (Participant)
  • Kevin Mcguinness (Participant)
  • Ashley Woodcock (Participant)

Impact: Health and wellbeing, Economic

Narrative

In collaboration with Manchester University NHS Foundation Trust (MFT) and industrial partner Vitalograph, we have developed the first accurate system to quantify coughing. The VitaloJAK, built with our algorithm technology has been used in 36 clinical trials to date, increasing the number of studies evaluating cough treatments. It is the only cough monitor approved for use in regulatory clinical trials in Europe and the US and has facilitated the development of the first potential treatment for refractory chronic cough (Gefapixant). Vitalograph’s CEO reports revenue of over GBP40,000,000 due to cough monitor adoption which also helped the company create 50 new jobs within UK and Ireland. In addition, it has brought over [text removed for publication] revenue into MFT from royalties, to March 2020.
Impact date1 Aug 2013 → 31 Dec 2020
Category of impactHealth and wellbeing, Economic
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute

Documents & Links

Related content